Neoadjuvant Sacituzumab Govitecan Displays Activity in Muscle-Invasive Bladder Cancer, But Questions Remain
Neoadjuvant sacituzumab govitecan demonstrated efficacy in patients with muscle-invasive bladder cancer, but its future role in the space is uncertain.
Source: onclive.com